



14 July 2020

ASX Announcement

BARDA funding for Pivotal Trial

PolyNovo is pleased to announce it has received funding of \$15M USD from BARDA to support the Pivotal trial program of NovoSorb BTM. PolyNovo will make a modest co-funding and “in kind” contribution to the trial with the final budget to be announced after US FDA approval.

The NovoSorb BTM trial will gather extensive data on the effectiveness of NovoSorb BTM in the treatment of full thickness burns enabling PolyNovo to apply for PMA approval from the US FDA for this treatment indication. Outside of the US NovoSorb BTM is already approved for use on full thickness burns.

Managing Director, Paul Brennan said, “*We appreciate BARDA’s ongoing commitment to NovoSorb BTM in funding this trial. Their substantial non-dilutive funding for this and other programs better enables PolyNovo to bring our innovative, life saving products to the US and the rest of the world.*”

This announcement has been authorised by Company Secretary, Jan-Marcel Gielen.

Further information:

Paul Brennan
Managing Director
Mobile: + 61 427 662 317



PolyNovo Limited
ABN 96 083 866 862

2/320 Lorimer Street
Port Melbourne
VIC Australia 3207

P +61 (0) 3 8681 4050
F +61 (0) 3 8681 4099

For personal use only

About BARDA

The PolyNovo Pivotal trial is being funded in part with federal funds from the U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number HHSO100201500021C_ModP00006. For more information on BARDA go to www.phe.gov/barda.

NovoSorb BTM advantage in disaster use

PolyNovo's NovoSorb[®] based BTM offers significant advantages compared with the current standard of care in its ability to generate a neo-dermis. BTM is scalable in production, robust yet easy to handle and apply, delivers outstanding cosmetic and functional outcomes. BTM provides a temporary scaffold allowing a new full dermis to be generated and then biodegrades leaving the patient's own tissue fully repaired.

About NovoSorb[®]

NovoSorb[®] is a novel range of bio-resorbable polymers that can be produced in many formats including, film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and programmable bio-resorption profile. NovoSorb[®] BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery or burn.

About PolyNovo[®]

PolyNovo is an Australian-based medical device company that designs, develops and manufactures dermal regeneration solutions (NovoSorb[®] BTM) using its patented NovoSorb[®] biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopaedic applications. For further information and market presentations see www.polynovo.com